NBIXHIGH SIGNALFINANCIAL10-K

NBIX delivered exceptional revenue growth of 166% alongside dramatically improved cash position, signaling strong commercial execution and robust financial health.

The massive revenue acceleration from $60.8M to $161.6M suggests NBIX's marketed products are gaining significant commercial traction, while the 206% increase in cash to $713M provides substantial runway for continued R&D investments. The combination of strong operating cash flow growth (+31.5%) and reduced share buybacks indicates management is prioritizing growth investments over capital returns.

Comparing 2026-02-11 vs 2025-02-10View on EDGAR →
FINANCIAL ANALYSIS

NBIX demonstrates remarkable financial momentum with revenue growing 166% while maintaining strong profitability (net income up 40% to $478.6M). The balance sheet strengthened significantly with cash nearly tripling to $713M and current assets expanding 46%, though current liabilities also rose 46% likely reflecting increased business activity. Operating cash flow grew a healthy 31.5% while management reduced share buybacks by 44%, suggesting a strategic shift toward reinvestment in the business during this high-growth phase.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
+206%
$233.0M$713.0M

Cash position surged 206% — strong cash generation or capital raise providing significant financial cushion.

Revenue
P&L
+165.9%
$60.8M$161.6M

Strong top-line growth of 165.9% — accelerating demand or successful expansion into new markets.

Current Liabilities
Balance Sheet
+46.4%
$507.7M$743.4M

Current liabilities surged 46.4% — significant near-term obligations; verify ability to meet short-term debt.

Current Assets
Balance Sheet
+46.3%
$1.7B$2.5B

Current assets grew 46.3% — improving short-term liquidity or inventory/receivables build.

Share Buybacks
Cash Flow
-44.1%
$300.0M$167.7M

Buyback activity reduced 44.1% — capital being redeployed elsewhere or cash conservation underway.

Accounts Receivable
Balance Sheet
+43.4%
$479.1M$686.8M

Receivables surged 43.4% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Net Income
P&L
+40.2%
$341.3M$478.6M

Net income grew 40.2% — bottom-line growth signals improving overall business health.

Interest Expense
P&L
-35.2%
$7.1M$4.6M

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

R&D Expense
P&L
+31.8%
$121.8M$160.5M

R&D investment increased 31.8% — signals commitment to future product development, though near-term margin impact.

Operating Cash Flow
Cash Flow
+31.5%
$595.4M$782.7M

Operating cash flow surged 31.5% — exceptional cash generation, highest quality earnings signal.

LANGUAGE CHANGES
NEW — 2026-02-11
PRIOR — 2025-02-10
ADDED
As of February 4, 2026, 100,363,463 shares of the registrant s common stock were outstanding.
Business Overview Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs.
We are dedicated to discovering, developing, and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine, and immunological disorders.
Food and Drug Administration (FDA) approved treatments for tardive dyskinesia (TD), chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (CAH), and endometriosis and uterine fibroids in collaboration with AbbVie Inc.
We estimate that TD affects approximately 800,000 people in the U.S., that approximately 90% of the 40,000 people in the U.S.
+7 more — sign up free →
REMOVED
(Exact name of registrant as specified in its charter) Delaware 33-0525145 (State or other jurisdiction of incorporation or organization) (I.R.S.
As of February 5, 2025, 99,703,527 shares of the registrant s common stock were outstanding.
ALKINDI, EFMODY, and other Neurocrine UK Limited trademarks are the property of Neurocrine UK Limited, a Neurocrine Biosciences company.
Business Overview Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options.
We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neuropsychiatric, neurological, and neuroendocrine disorders.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →